Collegium Pharmaceutical, Inc. COLL Segment — Interest Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s segment — interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s segment — interest expense?
- Collegium Pharmaceutical, Inc. (COLL) reported segment — interest expense of $15.86M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s segment — interest expense changed year-over-year?
- Collegium Pharmaceutical, Inc.'s segment — interest expense decreased by 23.7% year-over-year, from $20.79M to $15.86M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s segment — interest expense?
- Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s segment — interest expense has grown at a 9.2% compound annual growth rate (CAGR), from $63.21M to $82.31M.
- What does segment — interest expense mean?
- Reflects the cost of servicing the company's debt obligations, including interest payments on loans and credit facilities. This metric is a key indicator of the company's financial leverage and the burden of its capital structure on net income.